Harder-to-Treat Patients: Recognizing Them and Adapting Treatment Strategies

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Genetics

Background:

• Pharmacologic treatments have advanced for lowering low-density lipoprotein cholesterol (LDL-C) to reduce cardiovascular disease (CVD) risk.
• However, specific patient groups remain challenging to manage effectively.
• These include patients with familial hypercholesterolemia (FH) and those experiencing statin intolerance.

Purpose of the Study:

• To highlight the challenges in diagnosing and treating patients with persistently elevated lipid levels.
• To emphasize the need for standardized approaches in managing difficult-to-treat dyslipidemias.
• To address the clinical implications of undiagnosed familial hypercholesterolemia and statin intolerance on cardiovascular risk.

Main Methods:

• Review of existing literature on lipid-lowering therapies and cardiovascular risk reduction.
• Analysis of patient populations with familial hypercholesterolemia and statin intolerance.
• Discussion of diagnostic challenges and treatment guideline adherence.

Main Results:

• Familial hypercholesterolemia patients are often undiagnosed or undertreated, leading to high CVD risk.
• Statin intolerance is common, difficult to assess, and frequently results in suboptimal lipid management.
• Some patients do not respond adequately to standard guideline-based therapies.

Conclusions:

• A standardized approach is essential for the effective diagnosis and optimal treatment of difficult-to-treat lipid disorders.
• Improved diagnostic strategies and tailored treatment plans are needed for patients with familial hypercholesterolemia and statin intolerance.
• Addressing these challenges can significantly mitigate cardiovascular disease risk in vulnerable patient groups.